Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma

A children's oncology group report

Bruce Shiramizu, Stanton Goldman, Ian Kusao, Melissa Agsalda, James Lynch, Lynette M Smith, Lauren Harrison, Erin Morris, Thomas G. Gross, Warren Sanger, Sherrie Perkins, Mitchell S. Cairo

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Children/adolescents with mature B-cell non-Hodgkin lymphoma (B-NHL) have an excellent prognosis but relapses still occur. While chromosomal aberrations and/or clonal immunoglobulin (Ig) gene rearrangements may indicate risk of failure, a more universal approach was developed to detect minimal disease (MD). Children/adolescents with intermediate-risk B-NHL were treated with French-British-American/Lymphome Malins de Burkitt 96 (FAB/LMB96) B4 modified chemotherapy and rituximab. Specimens from diagnosis, end of induction (EOI), and end of therapy (EOT) were assayed for MD. Initial specimens were screened for IGHV family usage with primer pools followed by individual primers to identify MD. Thirty-two diagnostic/staging specimens screened positive with primer pools and unique IGHV family primers were identified. Two patients relapsed; first relapse (4months from diagnosis) was MD-positive at EOI, the second (36months from diagnosis) was MD-positive at EOT. At EOI, recurrent rates were similar between the MRD-positive and MRD-negative patients (P=0·40). At EOT, only 13/32 patients had MRD data available with one relapse in the MRD-positive group and no recurrences in the MRD-negative group (P=0·077). The study demonstrated molecular-disseminated disease in which IgIGHV primer pools could be used to assess MD. This feasibility study supports future investigations to assess the validity and significance of MD screening in a larger cohort of patients with intermediate-risk mature B-NHL.

Original languageEnglish (US)
Pages (from-to)758-763
Number of pages6
JournalBritish Journal of Haematology
Volume153
Issue number6
DOIs
StatePublished - Jun 1 2011

Fingerprint

B-Cell Lymphoma
Non-Hodgkin's Lymphoma
Recurrence
Therapeutics
Immunoglobulin Genes
Gene Rearrangement
Feasibility Studies
Chromosome Aberrations
Drug Therapy

Keywords

  • Immunoglobulin rearrangement
  • Lymphoma
  • Minimal residual disease
  • Non-Hodgkin lymphoma
  • Polymerase chain reaction

ASJC Scopus subject areas

  • Hematology

Cite this

Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma : A children's oncology group report. / Shiramizu, Bruce; Goldman, Stanton; Kusao, Ian; Agsalda, Melissa; Lynch, James; Smith, Lynette M; Harrison, Lauren; Morris, Erin; Gross, Thomas G.; Sanger, Warren; Perkins, Sherrie; Cairo, Mitchell S.

In: British Journal of Haematology, Vol. 153, No. 6, 01.06.2011, p. 758-763.

Research output: Contribution to journalArticle

Shiramizu, Bruce ; Goldman, Stanton ; Kusao, Ian ; Agsalda, Melissa ; Lynch, James ; Smith, Lynette M ; Harrison, Lauren ; Morris, Erin ; Gross, Thomas G. ; Sanger, Warren ; Perkins, Sherrie ; Cairo, Mitchell S. / Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma : A children's oncology group report. In: British Journal of Haematology. 2011 ; Vol. 153, No. 6. pp. 758-763.
@article{cba6df1d24e04beb92e62307181ccff0,
title = "Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma: A children's oncology group report",
abstract = "Children/adolescents with mature B-cell non-Hodgkin lymphoma (B-NHL) have an excellent prognosis but relapses still occur. While chromosomal aberrations and/or clonal immunoglobulin (Ig) gene rearrangements may indicate risk of failure, a more universal approach was developed to detect minimal disease (MD). Children/adolescents with intermediate-risk B-NHL were treated with French-British-American/Lymphome Malins de Burkitt 96 (FAB/LMB96) B4 modified chemotherapy and rituximab. Specimens from diagnosis, end of induction (EOI), and end of therapy (EOT) were assayed for MD. Initial specimens were screened for IGHV family usage with primer pools followed by individual primers to identify MD. Thirty-two diagnostic/staging specimens screened positive with primer pools and unique IGHV family primers were identified. Two patients relapsed; first relapse (4months from diagnosis) was MD-positive at EOI, the second (36months from diagnosis) was MD-positive at EOT. At EOI, recurrent rates were similar between the MRD-positive and MRD-negative patients (P=0·40). At EOT, only 13/32 patients had MRD data available with one relapse in the MRD-positive group and no recurrences in the MRD-negative group (P=0·077). The study demonstrated molecular-disseminated disease in which IgIGHV primer pools could be used to assess MD. This feasibility study supports future investigations to assess the validity and significance of MD screening in a larger cohort of patients with intermediate-risk mature B-NHL.",
keywords = "Immunoglobulin rearrangement, Lymphoma, Minimal residual disease, Non-Hodgkin lymphoma, Polymerase chain reaction",
author = "Bruce Shiramizu and Stanton Goldman and Ian Kusao and Melissa Agsalda and James Lynch and Smith, {Lynette M} and Lauren Harrison and Erin Morris and Gross, {Thomas G.} and Warren Sanger and Sherrie Perkins and Cairo, {Mitchell S.}",
year = "2011",
month = "6",
day = "1",
doi = "10.1111/j.1365-2141.2011.08681.x",
language = "English (US)",
volume = "153",
pages = "758--763",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Minimal disease assessment in the treatment of children and adolescents with intermediate-risk (Stage III/IV) B-cell non-Hodgkin lymphoma

T2 - A children's oncology group report

AU - Shiramizu, Bruce

AU - Goldman, Stanton

AU - Kusao, Ian

AU - Agsalda, Melissa

AU - Lynch, James

AU - Smith, Lynette M

AU - Harrison, Lauren

AU - Morris, Erin

AU - Gross, Thomas G.

AU - Sanger, Warren

AU - Perkins, Sherrie

AU - Cairo, Mitchell S.

PY - 2011/6/1

Y1 - 2011/6/1

N2 - Children/adolescents with mature B-cell non-Hodgkin lymphoma (B-NHL) have an excellent prognosis but relapses still occur. While chromosomal aberrations and/or clonal immunoglobulin (Ig) gene rearrangements may indicate risk of failure, a more universal approach was developed to detect minimal disease (MD). Children/adolescents with intermediate-risk B-NHL were treated with French-British-American/Lymphome Malins de Burkitt 96 (FAB/LMB96) B4 modified chemotherapy and rituximab. Specimens from diagnosis, end of induction (EOI), and end of therapy (EOT) were assayed for MD. Initial specimens were screened for IGHV family usage with primer pools followed by individual primers to identify MD. Thirty-two diagnostic/staging specimens screened positive with primer pools and unique IGHV family primers were identified. Two patients relapsed; first relapse (4months from diagnosis) was MD-positive at EOI, the second (36months from diagnosis) was MD-positive at EOT. At EOI, recurrent rates were similar between the MRD-positive and MRD-negative patients (P=0·40). At EOT, only 13/32 patients had MRD data available with one relapse in the MRD-positive group and no recurrences in the MRD-negative group (P=0·077). The study demonstrated molecular-disseminated disease in which IgIGHV primer pools could be used to assess MD. This feasibility study supports future investigations to assess the validity and significance of MD screening in a larger cohort of patients with intermediate-risk mature B-NHL.

AB - Children/adolescents with mature B-cell non-Hodgkin lymphoma (B-NHL) have an excellent prognosis but relapses still occur. While chromosomal aberrations and/or clonal immunoglobulin (Ig) gene rearrangements may indicate risk of failure, a more universal approach was developed to detect minimal disease (MD). Children/adolescents with intermediate-risk B-NHL were treated with French-British-American/Lymphome Malins de Burkitt 96 (FAB/LMB96) B4 modified chemotherapy and rituximab. Specimens from diagnosis, end of induction (EOI), and end of therapy (EOT) were assayed for MD. Initial specimens were screened for IGHV family usage with primer pools followed by individual primers to identify MD. Thirty-two diagnostic/staging specimens screened positive with primer pools and unique IGHV family primers were identified. Two patients relapsed; first relapse (4months from diagnosis) was MD-positive at EOI, the second (36months from diagnosis) was MD-positive at EOT. At EOI, recurrent rates were similar between the MRD-positive and MRD-negative patients (P=0·40). At EOT, only 13/32 patients had MRD data available with one relapse in the MRD-positive group and no recurrences in the MRD-negative group (P=0·077). The study demonstrated molecular-disseminated disease in which IgIGHV primer pools could be used to assess MD. This feasibility study supports future investigations to assess the validity and significance of MD screening in a larger cohort of patients with intermediate-risk mature B-NHL.

KW - Immunoglobulin rearrangement

KW - Lymphoma

KW - Minimal residual disease

KW - Non-Hodgkin lymphoma

KW - Polymerase chain reaction

UR - http://www.scopus.com/inward/record.url?scp=79957574866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79957574866&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2011.08681.x

DO - 10.1111/j.1365-2141.2011.08681.x

M3 - Article

VL - 153

SP - 758

EP - 763

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 6

ER -